CTECL Stock Overview
Engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
ConvaTec Group PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£2.36 |
| 52 Week High | UK£2.95 |
| 52 Week Low | UK£2.12 |
| Beta | 0.64 |
| 11 Month Change | 7.97% |
| 3 Month Change | 0.64% |
| 1 Year Change | 3.42% |
| 33 Year Change | 20.83% |
| 5 Year Change | 23.04% |
| Change since IPO | -6.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| CTECL | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -1.9% | -0.2% | 1.7% |
| 1Y | 3.4% | -2.3% | 8.3% |
Return vs Industry: CTECL exceeded the UK Medical Equipment industry which returned -2.3% over the past year.
Return vs Market: CTECL underperformed the UK Market which returned 8.3% over the past year.
Price Volatility
| CTECL volatility | |
|---|---|
| CTECL Average Weekly Movement | 6.7% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: CTECL has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: CTECL's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 10,000 | Karim Bitar | www.convatecgroup.com |
ConvaTec Group PLC engages in the development, manufacturing, and sale of medical products, services, and technologies in Europe, North America, and internationally. The company offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting from various conditions, such as diabetes, and acute conditions resulting from traumatic injury and burns. It also provides ostomy care solutions, including devices, accessories, and services for people with a stoma resulting from colorectal cancer, inflammatory bowel disease, and bladder cancer.
ConvaTec Group PLC Fundamentals Summary
| CTECL fundamental statistics | |
|---|---|
| Market cap | UK£4.83b |
| Earnings (TTM) | UK£122.26m |
| Revenue (TTM) | UK£1.76b |
39.5x
P/E Ratio2.7x
P/S RatioIs CTECL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTECL income statement (TTM) | |
|---|---|
| Revenue | US$2.20b |
| Cost of Revenue | US$970.50m |
| Gross Profit | US$1.23b |
| Other Expenses | US$1.08b |
| Earnings | US$153.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.075 |
| Gross Margin | 55.89% |
| Net Profit Margin | 6.96% |
| Debt/Equity Ratio | 80.4% |
How did CTECL perform over the long term?
See historical performance and comparison